CervoMed (CRVO)
3.18
-0.16 (4.79%)
Upcoming Events
Latest Headlines
H.C. Wainwright Reiterates Buy Rating on CervoMed (CRVO)
October 5, 2026 6:52 AM - StreetInsider
Form 8-K CervoMed Inc. For: Sep 28
September 28, 2026 5:08 PM - SEC Filing
CervoMed reports new neflamapimod tablet data, FDA lifts exposure cap
September 28, 2026 7:32 AM - StreetInsider
CervoMed Announces Pharmacokinetic Results with New Neflamapimod Oral Tablet Formulation and Secures FDA Removal of Drug Exposure Limit
September 28, 2026 7:30 AM - StreetInsider
CervoMed to Participate in the 5th Annual ROTH Healthcare Opportunities Conference
September 22, 2026 7:30 AM - StreetInsider
Form 8-K CervoMed Inc. For: Sep 10
September 10, 2026 4:08 PM - SEC Filing
CervoMed nfvPPA trial data to be presented at ISFTD meeting
September 10, 2026 7:30 AM - StreetInsider
CervoMed Announces Initial Results from the Phase 2a Clinical Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Have Been Accepted as a Late-Breaking Oral Session at ISFT
September 10, 2026 7:30 AM - StreetInsider
CervoMed to Participate in September Investor Conferences
September 8, 2026 7:30 AM - StreetInsider
Form SCHEDULE 13G/A CervoMed Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
August 14, 2026 4:48 PM - SEC Filing
Form SCHEDULE 13G/A CervoMed Inc. Filed by: CVI Investments, Inc.
August 14, 2026 2:42 PM - SEC Filing
Form SCHEDULE 13G CervoMed Inc. Filed by: Woodline Partners LP
August 14, 2026 11:03 AM - SEC Filing
Form SCHEDULE 13G CervoMed Inc. Filed by: ARMISTICE CAPITAL, LLC
August 14, 2026 10:09 AM - SEC Filing
CervoMed (CRVO) PT Lowered to $12 at Jones Trading
August 10, 2026 4:36 PM - StreetInsider
Form 8-K CervoMed Inc. For: Aug 10
August 10, 2026 4:08 PM - SEC Filing
CervoMed Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
August 10, 2026 7:30 AM - StreetInsider
CervoMed (CRVO) PT Lowered to $18 at Canaccord
August 10, 2026 7:00 AM - StreetInsider
Form S-8 CervoMed Inc.
August 7, 2026 4:55 PM - SEC Filing
Form 10-Q CervoMed Inc. For: Jun 30
August 7, 2026 4:27 PM - SEC Filing
CervoMed to Participate in Fireside Chat to Highlight Recent Progress in the Neflamapimod Clinical Development Program at the Canaccord Genuity 46th Annual Growth Conference
August 5, 2026 7:30 AM - StreetInsider
Form 8-K CervoMed Inc. For: Aug 04
August 4, 2026 7:52 AM - SEC Filing
CervoMed's neflamapimod receives UK innovation passport for DLB
August 4, 2026 6:00 AM - StreetInsider
CervoMed Announces Neflamapimod Awarded Innovation Passport Designation Under the UK Innovative Licensing and Access Pathway (ILAP) for Treatment of Dementia with Lewy Bodies (DLB)
August 4, 2026 5:15 AM - StreetInsider
H.C. Wainwright Reiterates Buy Rating on CervoMed (CRVO)
July 15, 2026 7:40 AM - StreetInsider
Form 8-K CervoMed Inc. For: Jul 14
July 14, 2026 4:21 PM - SEC Filing
CervoMed presents neflamapimod DLB trial data at AAIC 2026
July 14, 2026 7:32 AM - StreetInsider
CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB)
July 14, 2026 7:30 AM - StreetInsider
H.C. Wainwright Reiterates Buy Rating on CervoMed (CRVO)
July 13, 2026 6:40 AM - StreetInsider
Form EFFECT CervoMed Inc.
July 13, 2026 6:02 AM - SEC Filing
Form 424B3 CervoMed Inc.
July 10, 2026 5:27 PM - SEC Filing
Form 8-K CervoMed Inc. For: Jul 09
July 9, 2026 4:10 PM - SEC Filing
CervoMed completes enrollment in Phase 2 nfvPPA dementia trial
July 9, 2026 7:30 AM - StreetInsider
CervoMed Announces Completion of Enrollment in Phase 2 Study of Neflamapimod for Nonfluent Variant Primary Progressive Aphasia, a Type of Frontotemporal Dementia
July 9, 2026 7:30 AM - StreetInsider
H.C. Wainwright Reiterates Buy Rating on CervoMed (CRVO)
July 9, 2026 6:53 AM - StreetInsider
Full Article List
